Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Cahill Wealth Management LLC

Cahill Wealth Management LLC increased its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 11.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,295 shares of the biotechnology company’s stock after purchasing an additional 1,515 shares during the quarter. Cahill Wealth Management LLC’s holdings in Viking Therapeutics were worth $615,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of VKTX. The Manufacturers Life Insurance Company lifted its stake in Viking Therapeutics by 20.3% during the third quarter. The Manufacturers Life Insurance Company now owns 24,630 shares of the biotechnology company’s stock worth $1,559,000 after purchasing an additional 4,156 shares in the last quarter. Verition Fund Management LLC lifted its position in Viking Therapeutics by 80.6% in the third quarter. Verition Fund Management LLC now owns 7,721 shares of the biotechnology company’s stock valued at $489,000 after purchasing an additional 3,446 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of Viking Therapeutics during the 3rd quarter valued at approximately $308,000. Stifel Financial Corp raised its position in shares of Viking Therapeutics by 92.1% during the 3rd quarter. Stifel Financial Corp now owns 131,348 shares of the biotechnology company’s stock worth $8,316,000 after purchasing an additional 62,956 shares during the last quarter. Finally, National Bank of Canada FI grew its stake in Viking Therapeutics by 2,265.3% in the 3rd quarter. National Bank of Canada FI now owns 3,548 shares of the biotechnology company’s stock worth $225,000 after acquiring an additional 3,398 shares during the period. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Trading Up 9.9 %

VKTX opened at $21.97 on Thursday. Viking Therapeutics, Inc. has a 1-year low of $18.92 and a 1-year high of $81.86. The company’s 50 day moving average is $28.11 and its 200-day moving average is $43.77. The company has a market cap of $2.47 billion, a P/E ratio of -21.97 and a beta of 0.84.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.05). During the same quarter last year, the company posted ($0.25) EPS. On average, equities analysts forecast that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Wall Street Analyst Weigh In

VKTX has been the subject of a number of analyst reports. Maxim Group decreased their price objective on shares of Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating for the company in a research report on Friday, February 7th. The Goldman Sachs Group assumed coverage on shares of Viking Therapeutics in a research report on Tuesday. They set a “neutral” rating and a $30.00 price target on the stock. Scotiabank assumed coverage on shares of Viking Therapeutics in a research report on Thursday, February 13th. They set a “sector outperform” rating and a $102.00 price target on the stock. Raymond James increased their price target on shares of Viking Therapeutics from $122.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 6th. Finally, Citigroup initiated coverage on shares of Viking Therapeutics in a research note on Friday, February 7th. They set a “neutral” rating and a $38.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $89.75.

Insider Buying and Selling

In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of the firm’s stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the transaction, the director now owns 1,240 shares in the company, valued at approximately $29,946. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.70% of the stock is owned by insiders.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.